Moberg Pharma AB (publ) (STO:MOB)

Market Cap	474.71M +36.7%
Revenue (ttm)	14.59M +13.5%
Net Income	-25.73M
EPS	-0.56
Shares Out	47.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	186,179
Open	10.50
Previous Close	10.44
Day's Range	10.00 - 10.70
52-Week Range	7.53 - 14.12
Beta	1.08
Analysts	n/a
Price Target	n/a
Earnings Date	May 12, 2026

About Moberg Pharma AB

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 6
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MOB

Financial Performance

In 2025, Moberg Pharma AB's revenue was 13.54 million, an increase of 37.99% compared to the previous year's 9.81 million. Losses were -27.24 million, -89.32% less than in 2024.